| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 07/11/2001 | EP1113807A2 Cell mediated gene delivery using muscle derived cells for treating muscle- and bone-related injury or dysfunction |
| 07/11/2001 | EP1113800A1 Combinations of tetracyclic cyclic gmp-specific phosphodiesterase inhibitors with further therapeutic agents |
| 07/11/2001 | EP1113793A1 A new composition |
| 07/11/2001 | CN1303381A Dipeptidyl peptidase IV effectors |
| 07/11/2001 | CN1303380A Isothizole derivatives useful anticancer agents |
| 07/11/2001 | CN1303379A 2-Aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors |
| 07/11/2001 | CN1303372A New heterocyclically substituted amides, their production and their use |
| 07/11/2001 | CN1303368A 1 Alpha-hydroxy-25-ene-vitamin D, analogs and use thereof |
| 07/11/2001 | CN1303367A Nitric oxide synthase inhibitors |
| 07/11/2001 | CN1303301A Use of anti-gp 39 antibodies for treatment and/or reversal of lupus and associated kidney disease |
| 07/11/2001 | CN1068333C Sterol derivatives used as regulation of meiosis |
| 07/10/2001 | US6258948 An n-acylamino compound; antiinflammatory agents, autoimmune diseases |
| 07/10/2001 | US6258833 Enzyme inhibitors and antiinflammatory agents |
| 07/10/2001 | US6258824 Treatment of hyperproliferative diseases, such as cancers, in mammals. this invention also relates to a pharmaceutical compositions containing such compounds. |
| 07/10/2001 | US6258819 Substituted 2(4-piperidyl)-4(3H)-quinazolinones and 2-(4-piperidyl)-4(3H)-azaquinazolinones |
| 07/10/2001 | US6258817 Substituted pyrazin-2-yl-sulphonamide (-3-pyridyl) compounds and uses thereof |
| 07/10/2001 | US6258578 His5 |
| 07/10/2001 | US6258562 Human antibodies that bind human TNFα |
| 07/05/2001 | WO2001048153A1 Reconstructing organs from decellularized biomaterial scaffold |
| 07/05/2001 | WO2001047963A2 Inhibitors of complement activation, their preparation and use |
| 07/05/2001 | WO2001047934A1 Isoxazolo pyrimidinones and the use thereof |
| 07/05/2001 | WO2001047929A1 Triazolotriazinones and the use thereof |
| 07/05/2001 | WO2001047928A2 Imidazo 1,3,5 triazinones and the use thereof |
| 07/05/2001 | WO2001047921A1 Pyrimidine and triazine kinase inhibitors |
| 07/05/2001 | WO2001047915A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 07/05/2001 | WO2001047914A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 07/05/2001 | WO2001047905A1 Pyrrolidine derivatives as cyclic amp-specific phosphodiesterase inhibitors |
| 07/05/2001 | WO2001047901A1 Ox(adi)azolyl-hydroxamic acids useful as procollagen c-proteinase inhibitors |
| 07/05/2001 | WO2001047897A1 Cytokine, especially tnf-alpha, inhibitors |
| 07/05/2001 | WO2001047892A1 Tricyclic protein kinase inhibitors |
| 07/05/2001 | WO2001047886A1 Nitrile derivatives as cathepsin k inhibitors |
| 07/05/2001 | WO2001047885A1 Substituted indole mannich bases |
| 07/05/2001 | WO2001047880A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 07/05/2001 | WO2001047879A1 Pyrrolidines which inhibit camp-specific pde |
| 07/05/2001 | WO2001047878A1 Substituted pyrrole mannich bases to combat pain and allergic reactions |
| 07/05/2001 | WO2001047866A1 Substituted 1 and 2 naphthol mannich bases |
| 07/05/2001 | WO2001047859A1 Compounds active at the glucocorticoid receptor |
| 07/05/2001 | WO2001047533A2 INHIBITION OF GSK-3$g(b) |
| 07/05/2001 | WO2001047514A1 Use of hypoglycemic agent for treating impaired glucose metabolism |
| 07/05/2001 | WO2001012592A3 Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
| 07/05/2001 | WO2001003720A9 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 07/05/2001 | WO2000061622A3 Genes associated with diseases of the kidney |
| 07/05/2001 | WO2000055137A8 Compounds and methods for modulation of estrogen receptors |
| 07/05/2001 | WO2000052134A3 Inhibitors of prenyl-protein transferase |
| 07/05/2001 | US20010007020 Antibodies that bind to the nidogen-binding domain of laminin, their production and use |
| 07/05/2001 | US20010006982 Intravesicular instillation of certain homovanilloid compounds to humans experiencing neurogenic urinary dysfunction including urge; effective for those with spinal cord injury and multiple sclerosis; kits; dosage; no burning |
| 07/05/2001 | DE19963178A1 Substituierte Indol-Mannichbasen Substituted indole Mannich bases |
| 07/05/2001 | CA2396693A1 Cytokine, especially tnf-alpha, inhibitors |
| 07/05/2001 | CA2396579A1 Tricyclic protein kinase inhibitors |
| 07/05/2001 | CA2396502A1 Substituted pyrrole mannich bases |
| 07/05/2001 | CA2395663A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 07/05/2001 | CA2395548A1 Imidazo 1,3,5 triazinones and the use thereof |
| 07/05/2001 | CA2395543A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 07/05/2001 | CA2395418A1 Isoxazolo pyrimidinones and the use thereof |
| 07/05/2001 | CA2395410A1 Triazolotriazinones and the use thereof |
| 07/05/2001 | CA2395284A1 Inhibition of gsk-3.beta. |
| 07/05/2001 | CA2395179A1 Nitrile derivatives as cathepsin k inhibitors |
| 07/05/2001 | CA2395173A1 Pyrrolidines which inhibit camp-specific pde |
| 07/05/2001 | CA2394727A1 Pyrimidine and triazine kinase inhibitors |
| 07/05/2001 | CA2394098A1 Substituted 1 and 2 naphthol mannich bases |
| 07/05/2001 | CA2393583A1 Compounds active at the glucocorticoid receptor |
| 07/05/2001 | CA2393529A1 Inhibitors of complement activation, their preparation and use |
| 07/05/2001 | CA2392866A1 Substituted indole mannich bases |
| 07/04/2001 | EP1113013A1 Benzothiophene compounds, intermediates, compositions and methods |
| 07/04/2001 | EP1113007A1 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
| 07/04/2001 | EP1112361A2 Promotion or inhibition of angiogenesis and cardiovascularization |
| 07/04/2001 | EP1112286A1 Secreted proteins and polynucleotides encoding them |
| 07/04/2001 | EP1112266A1 Substituted 4-amino-2-aryl-pyrimidines, their production and use and pharmaceutical preparations containing same |
| 07/04/2001 | EP1112255A1 4,4-biarylpiperidine derivatives with opioid receptor activity |
| 07/04/2001 | EP1112088A1 Method for detecting, preventing, and treating renal disorders by modulating, regulating, and inhibiting connective tissue growth factor |
| 07/04/2001 | EP1112085A1 Antithrombotic agent and humanized anti-von willebrand factor monoclonal antibody |
| 07/04/2001 | EP1112083A2 Use of an angiogenic factor for the treatment of microvascular angiopathies |
| 07/04/2001 | EP1112082A2 Stable liquid formulations of botulinum toxin |
| 07/04/2001 | EP1112070A1 Novel substituted triazole compounds |
| 07/04/2001 | EP0850236B1 Piperazino derivatives as neurokinin antagonists |
| 07/04/2001 | CN1302296A Novel 2-alkyl substituted imidazole compounds |
| 07/04/2001 | CN1067899C Medicine for curing stone in urinary system |
| 07/03/2001 | US6255471 CRFG-1b, a target and marker for chronic renal failure |
| 07/03/2001 | US6255453 Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors |
| 07/03/2001 | US6255319 5-aryl-3-(8-azabicyclo[3.2.1]oct-3-yl)-1,3,4-oxadiazol-2(3H)-one derivatives as 5-ht4 receptor ligands |
| 07/03/2001 | US6255281 Complexing uteroglobin to fibronectin |
| 07/03/2001 | CA2101310C Novel arylglycinamide derivatives and preparative processes therefor |
| 06/30/2001 | CA2293852A1 Procedure for preparing active plant extracts used to trap free radicals; the extracts and compounds and devices containing them |
| 06/28/2001 | WO2001046405A2 Modulation of pax-2 for controlled apoptosis or survival of cells |
| 06/28/2001 | WO2001046263A1 Novel compounds |
| 06/28/2001 | WO2001046258A2 Transporters and ion channels |
| 06/28/2001 | WO2001046255A1 Nk cell receptor polynucleotides, polypeptides, and antibodies |
| 06/28/2001 | WO2001046196A1 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors |
| 06/28/2001 | WO2001046184A1 3-thiazol-4-yl-pyprolidine derivatives as amp-specific phosphodiesterase inhibitors |
| 06/28/2001 | WO2001046174A1 Novel compounds |
| 06/28/2001 | WO2001046172A1 Pyrazole cyclic amp-specific pde inhibitors |
| 06/28/2001 | WO2001046151A1 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| 06/28/2001 | WO2001046136A1 Hydrazone and oxime derivatives of pyrrolidine as amp-specific phosphodiesterase inhibitors |
| 06/28/2001 | WO2001045703A1 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use |
| 06/28/2001 | WO2001045695A2 Calcium formate for use as a phosphorus binder and a dietary supplement |
| 06/28/2001 | WO2001045663A2 USE OF AROMATIC POLYCYCLIC COMPOUNDS AS ACTIVATORS OF PPARs-TYPE RECEPTORS IN A COSMETIC OR PHARMACEUTICAL COMPOSITION |
| 06/28/2001 | WO2001005974A9 The il-1l1 gene and polypeptide products |
| 06/28/2001 | WO2001004148A3 Donor strand complemented pilin and adhesin broad-based vaccines |
| 06/28/2001 | WO2000078765A3 CHROMENO[4,3,2-de]ISOQUINOLINES AS POTENT DOPAMINE RECEPTOR LIGANDS |
| 06/28/2001 | WO2000078322A3 Combination of lactic acid bacteria and its use for the prevention and/or treatment of infections and inflammatory conditions |